These Biotech Stocks Could Soar 120% and 295%, According to Wall Street
Catalysts lie ahead for both of these companies.
Better Buy: Bluebird Bio Vs. Novavax
Who wins this face-to-face between two beaten-down biotechs?
Down 60% From Its 52-Week High, Is Novavax Stock a Buy?
Is there still too much risk surrounding this business?
1 Beaten-Down Stock to Buy and 1 to Avoid Like the Plague
These stocks could move in very different directions over the long run.
1 Beaten-Down Stock That's Still Not Worth Buying
For this biotech, a rebound seems far too unlikely.
Two Beaten-Down Stocks That Could Soar 170% and 630%, Respectively, According to Wall Street
Could these biotech companies still win in the vaccine market and beyond?
Is Novavax a Buy Now?
The stock has dropped 98% over the past three years.
1 of the Biggest Risks Facing Novavax Has Now Been Resolved: Is Now the Time to Buy the Stock?
Can the stock's recent rally continue?
Has Novavax Just Solved Its Biggest Problem?
The biotech company recently settled a dispute with a major customer.